Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 1, 2011, Pages 54-62

  Matafome, P ^a   Louro, T ^a   Rodrigues, L ^a   Crisostomo J ^a   Nunes, E ^a   Amaral, C ^a   Monteiro, P ^a,b   Cipriano, A ^b   Seica R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Atorvastatin; Inflammation; Liver disease; Metformin; Type 2 diabetes

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; METFORMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEPATITIS; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID LIVER LEVEL; LIVER FUNCTION; LIVER INJURY; LIVER PROTECTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FATTY LIVER; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERLEUKIN-6; LIVER; METFORMIN; OXIDATIVE STRESS; PYRROLES; RATS; RATS, INBRED STRAINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651103598     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1157     Document Type: Article

References (37)

1. Buginesi E, Gastaldelli A, Gambino R, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642.
2. Brownlee M. The pathobiology of diabetic complications. Diabetes 2005; 54: 1615-1625.
3. Chu N, Spiegelman D, Hotamisligil G, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001; 157: 495-503.
4. Hotamisligil G. Inflammatory pathways and insulin resistance. Int J Obes 2003; 27: S52-S55.
5. Yki-Järvinen H. Fat in liver and insulin resistance. Ann Med 2005; 37: 347-356.
6. Juge-Aubry C, Henrichot E, Meier C. Adipose tissue: a regulator of inflammation. J Clin Endoc Metab 2005; 19: 547-566.
7. Cave M, Deaciuc I, Mendez C, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 2007; 18: 184-195.
8. Grimsrud P, Picklo M, Griffin T, Bernlohr D. Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol C ell Prot 2007; 6: 624-637.
9. Bisgaier C, Essenburg A, Auerbach B, et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors inmice devoid of low density lipoprotein receptors. J Lipid Res 1997; 38: 2502-2525.
10. Paumelle R, Blanquart C, Briand O, et al. Acute anti-inflammatory properties of statins involve peroxisome proliferator-activated receptor-α via inhibition of the protein kinase C signalling pathway. Circ Res 2006; 98: 361-369.
11. Kim Y, Park K, Lee Y, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor. Diabetes 2008; 57: 306-314.
12. Federico A, Trappoliere C, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis 2006; 38: 789-801.
13. Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007; 56: 1418-1424.
14. Seiça RM, Suzuki KI, Santos RM, Rosário LM. Deficiência primária da secreção de insulina de ilhéus isolados de ratos Goto-Kakizaki, um modelo animal de diabetes tipo 2 não obesa. Acta Med Port 2004; 17: 42-48.
15. Nunes E, Peixoto F, Louro T, et al. Soybean oil treatment impairs glucose-stimulated insulin secretion and changes fatty acid composition of normal and diabetic islets. Acta Diabetol 2007; 44: 121-130.
16. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005; 54: 1914-1925.
17. Bayés B, Granada ML, Lauzurica R, et al. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 2005; 37: 3808-3812.
18. Hernandez T, Capell W, Wolfe P, Gerard L, Eckel R. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Am J Cardiol 2006; 98: 1656-1659.
19. Shetty G, Economides P, Horton E, Mantzoros C, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
20. Lam H, Chu C, Wei M, et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Bio Med 2006; 231: 1010-1015.
21. Wong V, Stavar L, Szeto L, et al. Atorvastatin induces insulin sensitization in Zucker fatty rats. Atherosclerosis 2006; 184: 348-355.
22. Ando H, Sugimoto K, Yanagihara H, et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008; 35: 1012-1017.
23. Satoh K, Keimatsu N, Kanda M, et al. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull 2005; 28: 2092-2095.
24. Chu C, Lee J, Lam H, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008; 31: 42-47.
25. Rotella C, Monami M, Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev 2006; 2: 307-315.
26. Eriksson A, Attvall S, Bonnier M, Eriksson J, Rosander B, Karlsson F. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab 2007; 9: 483-489.
27. Hsieh C, He C, Lee C, Wu L, Hung Y. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 1087-1092.
28. Eguchi K, Tomizawa H, Ishikawa J, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypert Res 2007; 30: 23-30.
29. Forst T, Pfützner A, Lübben G, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and pro-insulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT study. Metabolism 2007; 56: 491-496.
30. Mäuser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function and inhibition of glucose uptake. Eur J Pharm 2007; 564: 37-46.
31. von Eynatten M, Liu D, Bluemm A, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009; 71(1): 27-32.
32. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol. 2010; 8(5): 612-631.
33. Ekstedt M, Franzén L, Mathiesen U, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-141.
34. Georgescu E, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16: 39-46.
35. Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. Alim Pharmacol Ther 2006; 23: 1643-1647.
36. Tessari P, Tiengo A. Metformin treatment of rats with diet-induced overweight and hypertriglyceridemia decreases plasma triglyceride concentrations, while decreasing triglyceride and increasing ketone body output by the isolated perfused liver. Acta Diabetologica 2008; 45: 143-145.
37. Basu R, Shah P, Basu A, et al. Comparison of the effects of pioglitazone and metformin on hepatic and extrahepatic insulin action in people with type 2 diabetes. Diabetes 2008; 57: 24-31.